Royalty Pharma 

Yahoo Finance • 3 days ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company... Full story

Yahoo Finance • 10 days ago

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,... Full story

Yahoo Finance • 13 days ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independen... Full story

Yahoo Finance • 20 days ago

Peek Under The Hood: USSG Has 11% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 23 days ago

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The we... Full story

Yahoo Finance • 26 days ago

Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from... Full story

Yahoo Finance • last month

Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks. It is a lead... Full story

Yahoo Finance • last month

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

Royalty Pharma plc On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upsi... Full story

Yahoo Finance • last month

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market

First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital la... Full story

Yahoo Finance • last month

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:... Full story

Yahoo Finance • last month

Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes

(RTTNews) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950... Full story

Yahoo Finance • last month

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 millio... Full story

Yahoo Finance • last month

Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M

* Zenas BioPharma (NASDAQ:ZBIO [https://seekingalpha.com/symbol/ZBIO]), and Royalty Pharma (RPRX [https://seekingalpha.com/symbol/RPRX]) announced [https://seekingalpha.com/pr/20217104-zenas-biopharma-and-royalty-pharma-enter-into-obexel... Full story

Yahoo Finance • last month

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval fo... Full story

Yahoo Finance • last month

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA app... Full story

Yahoo Finance • last month

Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)?

Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$885 million upfront, with an option to purchase up to an additional US$65 million in royalties over the next 12 months. This trans... Full story

Yahoo Finance • 2 months ago

Royalty Pharma to buy royalty interest in Amgen’s lung cancer drug for up to $950 million

(Reuters) -Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen’s drug for small cell lung cancer for up to $950 million. The deal gives Royalty Pharma access to roughly 7% of glob... Full story

Yahoo Finance • 2 months ago

Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M

BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN]) cancer drug Imdelltra (tarlatamab-dll... Full story

Yahoo Finance • 2 months ago

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million

Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additiona... Full story

Yahoo Finance • 2 months ago

Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings

Technical breakout strategies focus on finding stocks with solid momentum that are pausing before their next upward move. By using a high ChartMill Technical Rating (which measures trend strength) along with a high Setup Quality Rating (wh... Full story